Report: Cancer Diagnostics Market to Grow from $776 mn to $5.3 bn: companiesandmarkets.com

• Global market for next generation cancer diagnostics market worth $776 mn
• Market set to grow to $5.3 billion by 2015
• Genomic and epigenomic analysis dominate the market

LONDON--(BUSINESS WIRE)--The total global annual market for next generation cancer diagnostics was $776 million in 2010, according to a new report available on companiesandmarkets.com. The market is growing at a compound annual growth rate (CAGR) of 47%, to reach a forecast market size of $5.3 billion in 2015.

Next-Generation Cancer Diagnostics: Technologies and Global Markets
http://www.companiesandmarkets.com/Market-Report/next-generation-cancer-diagnostics-technologies-and-global-markets-610154.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Genomic and epigenomic analysis dominate the next generation cancer diagnostics market and are expected to maintain leading positions in 2015. The epigenomics sector was valued at $18 million in 2010 and is expected to increase at a 102.6% compound annual growth rate (CAGR) to reach $614 million in 2015.

Demand for cellular analysis will also expand significantly during the next five years. This sector was worth $10 million in 2010 and is expected to increase at a 95.4% compound annual growth rate (CAGR) to reach $296 million in 2015.

Cancer is a collection of diseases caused by genetic malfunctions. The recent explosion in genomic and proteomic information since the completion of the Human Genome Project has created enormous diagnostic content that has been correlated with cancer progression. During this same time period, there has been tremendous scientific progress in novel analysis technologies, including lab-on-a-chip, RT-PCR, high-density microarrays, next generation sequencing, cellular capture and identification, and multiplexed assays.

These technological forces are merging with unmet medical diagnostic needs to create favorable conditions for future commercial growth. Thus, it is particularly timely to review the market opportunities and future growth of specific cancer diagnostic market segments.

The next generation cancer diagnostics industry is currently a small but growing segment of the in vitro diagnostics industry. Some tests are already established, for example in cervical cancer screening or breast cancer prognostics. A significant number of new assays using innovative platforms are in the diagnostic pipeline. For companies seeking to exploit the growth in this industry, it is important to understand the various next generation platforms and their development status for each cancer indication.

Report Details:
http://www.companiesandmarkets.com/Market-Report/next-generation-cancer-diagnostics-technologies-and-global-markets-610154.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2